Australia's green critical mineral opportunity

How can resource companies mitigate their carbon emissions in innovative ways? Proactive’s Phoebe Shields talks to CSIRO’s Dr Dia Milani, who leads the organisation’s CO2 utilisation team within the Sustainable Carbon Technologies group, about the urgency of including carbon capture and storage methods in the mix of tools to combat climate change – and the opportunities that abound for companies to apply the technology in Australia.

Artemis Resources Ltd executive director George Ventouras talks to Proactive’s Susanna Nelson about the company’s projects, mostly in the West Pilbara, where it is exploring for gold, copper and lithium. George also weighs in on ‘the white gold boom’, the importance of a diverse and sustainable mining industry to the Australian economy and the future of mining in this country.

China is our biggest trading partner. In this introduction to the topic, mining publisher and China entrepreneur Yolanda Torrisi tells Proactive about the Australian industries that are most exposed to the trading giant, whether diplomatic relations are starting to defrost, and how we can leverage the relationship to our best advantage at a time of uncertainty for global markets and supply chains.

Energy security is critical in these days of geopolitical unrest. Provaris Energy Ltd has seen the writing on the wall and has forged ahead with its business model of simple and efficient hydrogen production and transportation. MD and CEO Martin Carolan tells Proactive's Susanna Nelson the company is currently in the design phase of a prototype tank for compressed hydrogen, with construction and testing planned in Norway for the first quarter of 2024. A range of government and independent stakeholders are interested, too.

Clinical trials are, by necessity, subject to rigorous guidelines to protect human health. Proactive’s Phoebe Shields talks to Evrima founder and CEO Charlotte Bradshaw about her company’s data-driven patient matching system, which verifies and matches participants’ electronic medical records to trial protocols. This breaks down barriers to trial recruitment such as awareness, hospital-centricity, distribution of patients, commitment to participation and suitability to take part.

Clinical-stage immuno-oncology biotech Imugene has been making significant strides in the development of therapies targeting a range of cancers. In this episode of After Market, MD and CEO Leslie Chong tells Susanna Nelson about the company's Phase 1 metastatic advanced solid tumours, or MAST, trial, which has been designed to evaluate the safety and efficacy of the cancer-killing virus CF33-hNIS (VAXINIA).

The last few years have seen investors buffeted by the winds of pandemic and war, bringing with them supply chain issues, overcooked inflation and much-dreaded rate hikes. Atrium senior portfolio manager Brendan Paul talks to Proactive about why it’s an interesting time to be an investor, what risk really means and the importance of building a truly diverse asset portfolio in uncertain times.

Antimicrobial resistance means the age of antibiotics – when humanity has had the luxury of fixing or preventing all manner of disease with a simple biological agent in a capsule – is coming to an end. Recce Pharmaceuticals CEO James Graham talks to Proactive’s Susanna Nelson about how we stay one step ahead in the fight against deadly pathogens and avoid the next superbug.

The critical mineral boom is taking off. CSIRO senior principal research scientist and Green Mineral Technologies initiative leader Chris Vernon walks Proactive’s Phoebe Shields through the oncoming critical mineral supply dearth, the need for down-stream trade relationships and the potential effect of a circular economy on the mining industry.

What are the rules governing cannabis and psychedelics in Australia? How have attitudes to these substances changed over time, and what does the Australian biotech industry need governments to do to unlock the myriad therapeutic benefits they promise? Emyria's Dr Michael Winlo answers these questions and more in this interview with Proactive's Susanna Nelson.